



**Lorenz Risch**

## Contact

Lorenz Risch  
Switzerland

## Publications (25)

Kahlert C, Strahm C, Güsewell S, Cusini A, Brucher A, Goppel S, Möller E, Möller J, Ortner M, Ruetti M, Stocker R, Vuichard-Gysin D, Besold U, McGeer A, Risch L, Friedl A, Schlegel M, Vernazza P, Kuster S, Kohler P, SURPRISE (SURveillance of infectious diseases among health PRofessionals In SwitzErland) Study Group. Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study. *Clin Infect Dis* 2023; 77:194–202.

Kohler P, Babouee Flury B, Güsewell S, Egger T, Leal-Neto O, Brucher A, Lemmenmeier E, Meier Kleeb D, Möller J, Ortner M, Rieder P, Ruetti M, Schmid H, Stocker R, Vuichard-Gysin D, Speer O, Wiggli B, Besold U, McGeer A, Risch L, Friedl A, Schlegel M, Vernazza P, Kahlert C, Kuster S, SURPRISE Study Group. Clinical symptoms of SARS-CoV-2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals (SURPRISE study). *Influenza Other Respir Viruses* 2023; 17:e13167.

Sinnberg T, Lichtensteiger C, Ali O, Pop O, Risch L, Brugger S, Velic A, Bomze D, Kohler P, Vernazza P, Albrich W, Kahlert C, Abdou M, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Röcken M, Dulovic A, Shambat S, Ruetalo N, Buehler P, Scheier T, Jochum W, Kern L, Henz S, Schneider T, Kuster G, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy K, Spengler W, Brutsche M, Macek B, Twerenbold R, Penninger J, Matter M, Flatz L, Jochum A. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. *Am J Respir Crit Care Med* 2023; 207:38–49.

Babouee Flury B, Güsewell S, Egger T, Leal O, Brucher A, Lemmenmeier E, Meier Kleeb D, Möller J, Rieder P, Rütti M, Schmid H, Stocker R, Vuichard-Gysin D, Wiggli B, Besold U, McGeer A, Risch L, Friedl A, Schlegel M, Kuster S, Kahlert C, Kohler P, SURPRISE Study Group. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland—A multicentre cohort study. *PLoS Med* 2022; 19:e1004125.

Strahm C, Seneghini M, Güsewell S, Egger T, Leal-Neto O, Brucher A, Lemmenmeier E, Meier Kleeb D, Möller J, Rieder P, Ruetti M, Rutz R, Schmid H, Stocker R, Vuichard-Gysin D, Wiggli B, Besold U, Kuster S, McGeer A, Risch L, Friedl A, Schlegel M, Schmid D, Vernazza P, Kahlert C, Kohler P. Symptoms Compatible With Long Coronavirus Disease (COVID) in Healthcare Workers With and Without Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection—Results of a Prospective Multicenter Cohort. *Clin Infect Dis* 2022; 75:e1011–e1019–9.

Sumer J, Schlegel M, Vernazza P, Seneghini M, Nigg S, Risch L, Mueller N, Kahlert C, Flury D, Kohler P. Safety Evaluation of a Medical Congress Held During the COVID-19 Pandemic—A Prospective Cohort. *Int J Public Health* 2022; 67:1604147.

Haller S, Vuichard-Gysin D, Wiggli B, Besold U, Kuster S, McGeer A, Risch L, Schlegel M, Friedl A, Vernazza P, Kahlert C, Stocker R, Rütti M, Güsewell S, Egger T, Scanferla G, Thoma R, Leal-Neto O, Flury D, Brucher A, Lemmenmeier E, Möller J, Rieder P, Kohler P. Impact of respirator versus surgical masks on SARS-CoV-2 acquisition in healthcare workers: a prospective multicentre cohort. *Antimicrob Resist Infect Control* 2022; 11:27.

Kohler P, Jonsdottir H, Risch L, Vernazza P, Ackermann-Gäumann R, Kahlert C. No neutralizing effect of pre-existing tick-borne encephalitis virus antibodies against severe acute respiratory syndrome coronavirus-2: a prospective healthcare worker study. *Sci Rep* 2021; 11:24198.

Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. *J Cancer Res Clin Oncol* 2021; 148:647–656.

Hasan Ali O, Bomze D, Risch L, Brugger S, Paprotny M, Weber M, Thiel S, Kern L, Albrich W, Kohler P, Kahlert C, Vernazza P, Bübler P, Schüpbach R, Gómez-Mejia A, Popa A, Bergthaler A, Penninger J, Flatz L. Erratum to: Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. *Clin Infect Dis* 2021; 73:1746.

Kohler P, Wiggli B, Besold U, Kuster S, McGeer A, Risch L, Friedl A, Schlegel M, Vernazza P, Vuichard-Gysin D, Stocker R, Ruetti M, Güsewell S, Seneghini M, Egger T, Leal O, Brucher A, Lemmenmeier E, Möller J, Rieder P, Kahlert C. Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19-a prospective multicenter cohort study. *BMC Med* 2021; 19:270.

Kahlert C, Albrich W, Babouee Flury B, Besold U, Fehr J, Kuster S, McGeer A, Risch L, Schlegel M, Friedl A, Vernazza P, Wiggli B, Vuichard-Gysin D, Stocker R, Persi R, Güsewell S, Egger T, Leal-Neto O, Sumer J, Flury D, Brucher A, Lemmenmeier E, Möller J, Rieder P, Kohler P. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study. *Clin Microbiol Infect* 2021; 27:1336-1344.

Weber M, Imperiali M, Salimi Y, Fleisch F, Cusini A, Heer S, Renz H, Paprotny M, Kohler P, Vernazza P, Risch L, Bodmer T, Egli K, Risch M, Thiel S, Grossmann K, Nigg S, Wohlwend N, Lung T, Hillmann D, Ritzler M, Ferrara F, Bigler S, Kahlert C. Characteristics of Three Different Chemiluminescence Assays for Testing for SARS-CoV-2 Antibodies. *Dis Markers* 2021; 2021:8810196.

Hasan Ali O, Penninger J, Bergthaler A, Popa A, Gómez-Mejia A, Schüpbach R, Bübler P, Vernazza P, Kahlert C, Kohler P, Albrich W, Kern L, Thiel S, Weber M, Paprotny M, Brugger S, Risch L, Bomze D, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. *Clin Infect Dis* 2021; 73:e2869-e2874.

Vernazza P, Risch L, Lange K, Esson C, Hauser C, Aebi-Popp K, Stoffel M, Dost F, Ritzler M, Rasi M, Schmidt A. The Swiss STAR trial - an evaluation of target groups for sexually transmitted infection screening in the sub-sample of women. *Swiss Med Wkly* 2020; 150:w20393.

Schaffner A, Bodmer T, Imperiali M, Renz H, Kohler P, Vernazza P, Kahlert C, Twerenbold R, Paprotny M, Conen D, Bigler S, Hillmann D, Lung T, Risch L, Aeschbacher S, Risch C, Weber M, Thiel S, Jüngert K, Pichler M, Grossmann K, Wohlwend N, Risch M. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. *J Clin Med* 2020; 9

Risch M, Imperiali M, Salimi Y, Fleisch F, Cusini A, Renz H, Kohler P, Vernazza P, Kahlert C, Paprotny M, Bodmer T, Egli K, Weber M, Thiel S, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Ferrara F, Bigler S, Risch L. Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation. *Biomed Res Int* 2020; 2020:9878453.

Thiel S, Copeland S, Karajan T, Cusini A, Fleisch F, Kahlert C, Vernazza P, Risch M, Ritzler M, Hillmann D, Lung T, Wohlwend N, Risch L, Weber M, Paprotny M. Flattening the curve in 52 days: characterisation of the COVID-19 pandemic in the Principality of Liechtenstein - an observational study. *Swiss Med Wkly* 2020; 150:w20361.

Kohler P, Schlegel M, Risch L, Kuster S, McGeer A, Babouee Flury B, Albrich W, Notter J, Leal-Neto O, Güsewell S, Flury D, Sumer J, Kahlert C, Vernazza P. Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study. *Infect Control Hosp Epidemiol* 2020; 42:604-608.

Baron R, Bodmer T, Imperiali M, Heer S, Renz H, Flatz L, Kohler P, Vernazza P, Kahlert C, Paprotny M, Ferrara F, Egli K, Risch L, Weber M, Thiel S, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Bigler S, Risch M. Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study. *Clin Chem Lab Med* 2020; 58:2131-2140.

Kovac M, Egli K, Imperiali M, Heer S, Salimi Y, Renz H, Kohler P, Vernazza P, Kahlert C, Paprotny M, Bodmer T, Ferrara F, Risch L, Thiel S, Weber M, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Bigler S, Risch M. EDTA-Anticoagulated Whole Blood for SARS-CoV-2 Antibody Testing by Electrochemiluminescence Immunoassay (ECLIA) and Enzyme-Linked Immunosorbent Assay (ELISA). *Diagnostics (Basel)* 2020; 10

Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89–93.

Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Pichler Hefti J, Weinberger K, Merz T, Maggiorini M, Bloch K, Hess T, Turk A, Schoch O, Risch L, Hefti U, Sonntag D, Huber A. Oxidative stress in hypobaric hypoxia and influence on vessel-tone modifying mediators. *High Alt Med Biol* 2013; 14:273–9.

Pichler Hefti J, Maggiorini M, Schoch O, Barthelmess D, Bosch M, Turk A, Merz T, Risch G, Scharrer I, Hefti U, Risch L, Huber A. Changes of coagulation parameters during high altitude expedition. *Swiss Med Wkly* 2010; 140:111–7.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)